Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y Logunov; Inna V Dolzhikova; Dmitry V Shcheblyakov; Amir I Tukhvatulin; Olga V Zubkova; Alina S Dzharullaeva; Anna V Kovyrshina; Nadezhda L Lubenets; Daria M Grousova; Alina S Erokhova; Andrei G Botikov; Fatima M Izhaeva; Olga Popova; Tatiana A Ozharovskaya; Ilias B Esmagambetov; Irina A Favorskaya; Denis I Zrelkin; Daria V Voronina; Dmitry N Shcherbinin; Alexander S Semikhin; Yana V Simakova; Elizaveta A Tokarskaya; Daria A Egorova; Maksim M Shmarov; Natalia A Nikitenko; Vladimir A Gushchin; Elena A Smolyarchuk; Sergey K Zyryanov; Sergei V Borisevich; Boris S Naroditsky; Alexander L Gintsburg

The Lancet (2021) - Comments
doi: 10.1016/s0140-6736(21)00234-8 issn: 0140-6736 pubmed: 33545094 issn: 1474-547x

Denis Y Logunov, Inna V Dolzhikova, Dmitry V Shcheblyakov, Amir I Tukhvatulin, Olga V Zubkova, Alina S Dzharullaeva, Anna V Kovyrshina, Nadezhda L Lubenets, Daria M Grousova, Alina S Erokhova, Andrei G Botikov, Fatima M Izhaeva, Olga Popova, Tatiana A Ozharovskaya, Ilias B Esmagambetov, Irina A Favorskaya, Denis I Zrelkin, Daria V Voronina, Dmitry N Shcherbinin, Alexander S Semikhin